Who makes pIRS2-phosphopeptide?

pIRS2-phosphopeptide is developed by Craig L Slingluff, Jr.

What development phase is pIRS2-phosphopeptide in?

pIRS2-phosphopeptide is in Phase 1.

Last reviewed 2026-04-19 · How we verify

pIRS2-phosphopeptide

Craig L Slingluff, Jr · Phase 1 active Biologic

At a glance

Generic name	pIRS2-phosphopeptide
Sponsor	Craig L Slingluff, Jr
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

pIRS2-phosphopeptide CI brief — competitive landscape report
pIRS2-phosphopeptide updates RSS · CI watch RSS
Craig L Slingluff, Jr portfolio CI